| Mrs Amelia Noel, M ED | |
|
2508 Colorado Dr, Marrero, LA 70072-6127 | |
| (504) 261-0222 | |
| Not Available |
| Full Name | Mrs Amelia Noel |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 2508 Colorado Dr, Marrero, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043685696 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Amelia Noel, M ED 2508 Colorado Dr, Marrero, LA 70072-6127 Ph: (504) 261-0222 | Mrs Amelia Noel, M ED 2508 Colorado Dr, Marrero, LA 70072-6127 Ph: (504) 261-0222 |
News Archive
Myriad Genetics, Inc. today announced the launch of PANEXIA™, a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. PANEXIA, Myriad's ninth molecular diagnostic product, is the second product launched by the Company this year.
Older Americans are increasingly active, and this lifestyle shift has contributed to the rise in average age of a person experiencing a spinal cord injury. The changing demographic calls for a better understanding of how aging impacts recovery and repair after a spinal cord injury.
A so-called "tooth-on-a-chip" could one day enable more personalized dentistry, giving dentists the ability to identify dental filling materials that work better and last longer based on a patient's own teeth and oral microbiome.
Using brain tumor samples collected from children in the United States and Europe, an international team of scientists found that the drug panobinostat and similar gene regulating drugs may be effective at treating diffuse intrinsic pontine gliomas (DIPG), an aggressive and lethal form of pediatric cancer.
A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.
› Verified 7 days ago
Princess-india Philicie Powell, LPC,NCC Counselor Medicare: Not Enrolled in Medicare Practice Location: 5001 Westbank Expy Ste 100, Marrero, LA 70072 Phone: 504-349-8801 | |
Jasmine Hall, Counselor Medicare: Not Enrolled in Medicare Practice Location: 6217 West Bank Expressway, Marrero, LA 70072 Phone: 504-533-9761 | |
Juaniece Smith, Counselor Medicare: Not Enrolled in Medicare Practice Location: 5001 Westbank Expy, Marrero, LA 70072 Phone: 504-838-5215 | |
Jamila Ricketts, Counselor Medicare: Not Enrolled in Medicare Practice Location: 931 Westwood Dr Ste E, Marrero, LA 70072 Phone: 504-340-8880 | |
Ms. Lisa Ray, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 5001 Westbank Expy, Marrero, LA 70072 Phone: 504-349-8708 Fax: 504-349-8768 | |
Ms. Barbara Ann Oliva, Counselor Medicare: Not Enrolled in Medicare Practice Location: 5001 Westbank Expy, Marrero, LA 70072 Phone: 504-349-8833 |